A Comprehensive Systematic Review of Natural Biomedicines for Immune-Mediated and Inflammatory Dermatologic Diseases.

IF 2.7 3区医学 Q2 PHARMACOLOGY & PHARMACY

Clinical Drug Investigation Pub Date : 2025-05-01 Epub Date: 2025-04-28 DOI:10.1007/s40261-025-01441-y

Promise Ufomadu, Camille F Villar, Stephanie Y Zhang, Aileen Y Hu, Oyetawa Asempa

{"title":"A Comprehensive Systematic Review of Natural Biomedicines for Immune-Mediated and Inflammatory Dermatologic Diseases.","authors":"Promise Ufomadu, Camille F Villar, Stephanie Y Zhang, Aileen Y Hu, Oyetawa Asempa","doi":"10.1007/s40261-025-01441-y","DOIUrl":null,"url":null,"abstract":"Background: Natural biomedicines (NBMs) are frequently used to manage immune-mediated and inflammatory dermatologic diseases (IMIDDs). This systematic review evaluates the efficacy, safety, and clinical relevance of NBMs in IMIDDs, providing an evidence-based analysis to guide dermatologic practice.Methods: Following PRISMA guidelines, a systematic search was conducted in PubMed, Embase, Medline, and Google Scholar for randomized controlled trials (RCTs) investigating NBMs in IMIDDs from 1990 to 2023. Studies were included if they met predefined eligibility criteria: RCT design, relevant IMIDD condition, NBM intervention, and quantitative outcome measures. Risk of bias was assessed using the Jadad scale. Results were synthesized qualitatively due to heterogeneity in study designs and outcome measures.Results: Of 1364 records screened, 95 RCTs were included, encompassing 5265 participants across 23 countries. Indigo naturalis, fish oil (⍵-3), and aloe vera demonstrated the most consistent efficacy in managing psoriasis, systemic lupus erythematosus (SLE), atopic dermatitis (AD), and lichen planus (LP). Indigo naturalis significantly improved erythema, scaling, and PASI scores in psoriasis patients. Fish oil showed benefits in SLE disease activity indices and AD severity, while aloe vera demonstrated improvements in SCORAD and LP severity criteria. Most NBMs exhibited favorable safety profiles, although adverse event reporting was inconsistent.Discussion: While these findings highlight the potential of NBMs in dermatologic care, methodological limitations, including small sample sizes, heterogeneity in study designs, and lack of direct comparisons to conventional therapies, limit definitive conclusions. Additionally, not all natural agents can be easily searched and captured in systematic reviews, which may have restricted the scope of included NBMs. Future research should emphasize high-quality RCTs, standardized outcome measures, and comparative studies against conventional treatments.Trial registration: The review protocol is registered with Open Science Framework (OSF) ( https://doi.org/10.17605/OSF.IO/UH9XJ ).","PeriodicalId":10402,"journal":{"name":"Clinical Drug Investigation","volume":"45 5","pages":"255-270"},"PeriodicalIF":2.7000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Drug Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40261-025-01441-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Natural biomedicines (NBMs) are frequently used to manage immune-mediated and inflammatory dermatologic diseases (IMIDDs). This systematic review evaluates the efficacy, safety, and clinical relevance of NBMs in IMIDDs, providing an evidence-based analysis to guide dermatologic practice.

Methods: Following PRISMA guidelines, a systematic search was conducted in PubMed, Embase, Medline, and Google Scholar for randomized controlled trials (RCTs) investigating NBMs in IMIDDs from 1990 to 2023. Studies were included if they met predefined eligibility criteria: RCT design, relevant IMIDD condition, NBM intervention, and quantitative outcome measures. Risk of bias was assessed using the Jadad scale. Results were synthesized qualitatively due to heterogeneity in study designs and outcome measures.

Results: Of 1364 records screened, 95 RCTs were included, encompassing 5265 participants across 23 countries. Indigo naturalis, fish oil (⍵-3), and aloe vera demonstrated the most consistent efficacy in managing psoriasis, systemic lupus erythematosus (SLE), atopic dermatitis (AD), and lichen planus (LP). Indigo naturalis significantly improved erythema, scaling, and PASI scores in psoriasis patients. Fish oil showed benefits in SLE disease activity indices and AD severity, while aloe vera demonstrated improvements in SCORAD and LP severity criteria. Most NBMs exhibited favorable safety profiles, although adverse event reporting was inconsistent.

Discussion: While these findings highlight the potential of NBMs in dermatologic care, methodological limitations, including small sample sizes, heterogeneity in study designs, and lack of direct comparisons to conventional therapies, limit definitive conclusions. Additionally, not all natural agents can be easily searched and captured in systematic reviews, which may have restricted the scope of included NBMs. Future research should emphasize high-quality RCTs, standardized outcome measures, and comparative studies against conventional treatments.

Trial registration: The review protocol is registered with Open Science Framework (OSF) ( https://doi.org/10.17605/OSF.IO/UH9XJ ).

查看原文本刊更多论文

免疫介导和炎症性皮肤病的天然生物医学综合系统综述。

背景：天然生物医学（nbm）经常被用于治疗免疫介导性和炎症性皮肤病（IMIDDs）。本系统综述评估了nbm治疗imidd的疗效、安全性和临床相关性，为指导皮肤科实践提供了循证分析。方法：遵循PRISMA指南，系统检索PubMed、Embase、Medline和谷歌Scholar，检索1990年至2023年调查imidd中NBMs的随机对照试验（RCTs）。如果研究符合预定义的资格标准：随机对照试验设计、相关的IMIDD条件、NBM干预和定量结果测量，则纳入研究。偏倚风险采用Jadad量表进行评估。由于研究设计和结果测量的异质性，对结果进行了定性综合。结果：在筛选的1364条记录中，纳入了95项随机对照试验，包括来自23个国家的5265名参与者。靛蓝、鱼油（condition -3）和芦荟在治疗牛皮癣、系统性红斑狼疮（SLE）、特应性皮炎（AD）和扁平苔藓（LP）方面表现出最一致的疗效。靛蓝可显著改善银屑病患者的红斑、脱屑和PASI评分。鱼油显示SLE疾病活动指数和AD严重程度的益处，而芦荟显示SCORAD和LP严重程度标准的改善。尽管不良事件报告不一致，但大多数NBMs表现出良好的安全性。讨论：虽然这些发现强调了NBMs在皮肤病学治疗中的潜力，但方法学上的局限性，包括样本量小、研究设计的异质性以及缺乏与传统疗法的直接比较，限制了明确的结论。此外，并不是所有的天然制剂都可以在系统评价中容易地搜索和捕获，这可能限制了纳入NBMs的范围。未来的研究应强调高质量的随机对照试验、标准化的结果测量和与常规治疗的比较研究。试验注册：审查方案已在开放科学框架（OSF）注册（https://doi.org/10.17605/OSF.IO/UH9XJ）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Drug Investigation 医学-药学

CiteScore

5.90

自引率

3.10%

发文量

108

审稿时长

6-12 weeks

期刊介绍： Clinical Drug Investigation provides rapid publication of original research covering all phases of clinical drug development and therapeutic use of drugs. The Journal includes: -Clinical trials, outcomes research, clinical pharmacoeconomic studies and pharmacoepidemiology studies with a strong link to optimum prescribing practice for a drug or group of drugs. -Clinical pharmacodynamic and clinical pharmacokinetic studies with a strong link to clinical practice. -Pharmacodynamic and pharmacokinetic studies in healthy volunteers in which significant implications for clinical prescribing are discussed. -Studies focusing on the application of drug delivery technology in healthcare. -Short communications and case study reports that meet the above criteria will also be considered. Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Clinical Drug Investigation may be accompanied by plain language summaries to assist readers who have some knowledge, but non in-depth expertise in, the area to understand important medical advances.